-logo-1200x675.png?v=20220915161652&w=240&h=240&zc=2){kind=logo}
Intellia Therapeutics (NASDAQ:NTLA) Receives “Sell” Rating from The Goldman Sachs Group
The Goldman Sachs Group reissued their sell rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note issued to investors on Friday, MarketBeat Ratings reports. The Goldman Sachs Group currently has a $9.00 target price on the stock. Several other research firms have also issued reports on NTLA. Canaccord Genuity Group […]
The Goldman Sachs Group reissued their sell rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note issued to investors on Friday, MarketBeat Ratings reports. The Goldman Sachs Group currently has a $9.00 target price on the stock. Several other research firms have also issued reports on NTLA. Canaccord Genuity Group […]
